1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,000 | 10.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Tevogen Bio Holdings Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 26.03. | Tevogen Bio Inc: Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth | 235 | GlobeNewswire (Europe) | Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates... ► Artikel lesen | |
| 25.03. | Tevogen Bio erfüllt nach Aktienzusammenlegung wieder Nasdaq-Anforderungen | 3 | Investing.com Deutsch | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 25.03. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Tevogen Bio Inc: Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement | 158 | GlobeNewswire (Europe) | WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization | 317 | GlobeNewswire (Europe) | Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen.AI Reports Advancements in PredicTcell Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure | 377 | GlobeNewswire (Europe) | WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform... ► Artikel lesen | |
| 11.03. | Tevogen Bio Inc: Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform | 2 | GlobeNewswire (USA) | ||
| 09.03. | Tevogen Bio Inc: Tevogen Names Leadership Team to Execute Diversified Growth Strategy | 365 | GlobeNewswire (Europe) | WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business verticals... ► Artikel lesen | |
| 06.03. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 652 | GlobeNewswire (Europe) | WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve... ► Artikel lesen | |
| 06.03. | Tevogen Bio Explores Buyout To Boost Generics Platform | 6 | Benzinga.com | ||
| 06.03. | XFRA G280: AUSSETZUNG/SUSPENSION | 247 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILTEVOGEN BIO HLDGS... ► Artikel lesen | |
| 06.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 06.03.2026 | 326 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.03.2026
Aktien
1 CA3027351053 Fab-Form Industries... ► Artikel lesen | |
| 05.03. | Tevogen Bio Inc: Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical | 223 | GlobeNewswire (Europe) | WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| 05.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.03.2026 | 527 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 05.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.03.2026.ISIN NameCA37640A4028 GLACIER... ► Artikel lesen | |
| 05.03. | XFRA ISIN CHANGE | 357 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA37640A4028 Glacier Lake Resources Inc. 05.03.2026 CA83058E1060 Glacier Lake Resources Inc. 06.03.2026 Tausch 2,4:1US88165K1016 Tevogen... ► Artikel lesen | |
| 04.03. | Tevogen approves 1-for-50 reverse share split | 3 | Seeking Alpha | ||
| 04.03. | Tevogen Bio Inc: Tevogen Announces Reverse Stock Split | 205 | GlobeNewswire (Europe) | WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that its Board of Directors (the "Board") has approved a reverse... ► Artikel lesen | |
| 03.03. | D. Boral Capital senkt Kursziel für Tevogen Bio wegen Verwässerungsrisiko auf 2 $ | 5 | Investing.com Deutsch | ||
| 03.03. | D. Boral Capital lowers Tevogen Bio stock price target to $2 on dilution risk | 3 | Investing.com |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| PALATIN TECHNOLOGIES | 17,950 | -3,49 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 631,90 | -1,06 % | Piper Sandler reiterates Overweight rating on Regeneron stock at $875 | ||
| INOVIO PHARMACEUTICALS | 0,917 | +0,94 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| COSCIENS BIOPHARMA | 1,740 | -0,57 % | Cosciens Biopharma Inc: Cosciens Biopharma does not say why shares are spiking | ||
| BIOMARIN PHARMACEUTICAL | 46,550 | +0,11 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 55,36 | 0,00 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| XOMA ROYALTY | 30,600 | +5,52 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| PHIO PHARMACEUTICALS | 1,215 | -3,19 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 | King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ORAGENICS | 0,606 | 0,00 % | Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal... ► Artikel lesen | |
| INSMED | 131,50 | -0,41 % | Insmed Incorporated: Insmed Provides Clinical Update on Phase 2b CEDAR Study | -Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program-
-Safety Was Consistent with Previous Studies and No New Safety... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM | 37,140 | +0,11 % | Sobi, Inc.: Sobi Receives Health Canada Approval for EMPAVELI (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN | EMPAVELI (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced... ► Artikel lesen |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,68 % bei einem Aktienkurs von 5,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.